Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach

Journal of Pharmaceutical Sciences

Volumn 105, Issue 4, 2016, Pages 1513-1518

  Vourli, Sophia ^a   Tsala, Marilena ^a   Kotsakis, Stathis ^b   Daikos, George L ^c   Tzouvelekis, Leonidas ^d   Miriagou, Vivi ^b   Zerva, Loukia ^a   Meletiadis, Joseph ^a,e  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Klebsiella pneumoniae; meropenem; metallo beta lactamases; prolonged infusion; VIM

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; SHORT COURSE THERAPY; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; DRUG EFFECTS; EQUIPMENT DESIGN; INFUSION PUMP; KLEBSIELLA INFECTIONS; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; EQUIPMENT DESIGN; FEMALE; HUMANS; INFUSION PUMPS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; THIENAMYCINS; YOUNG ADULT;

EID: 84964430149     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.02.008     Document Type: Article

References (24)

1. R. Podschun, and U. Ullmann Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors Clin Microbiol Rev 11 1998 589 603
2. L.S. Tzouvelekis, A. Markogiannakis, M. Psichogiou, P.T. Tassios, and G.L. Daikos Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions Clin Microbiol Rev 25 2012 682 707
3. G.L. Daikos, P. Petrikkos, M. Psichogiou, and et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections Antimicrobial Agents Chemother 53 2009 1868 1873
4. A. Loli, L.S. Tzouvelekis, E. Tzelepi, and et al. Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1 J Antimicrob Chemother 58 2006 669 672
5. D.P. Nicolau Pharmacokinetic and pharmacodynamic properties of meropenem Clin Infect Dis 47 suppl 1 2008 S32 S40
6. C. Li, J.L. Kuti, C.H. Nightingale, and D.P. Nicolau Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients J Clin Pharmacol 46 2006 1171 1178
7. G. Woodnutt Pharmacodynamics to combat resistance J Antimicrob Chemother 46 suppl T 2000 25 31
8. S. Jaruratanasirikul, S. Sriwiriyajan, and J. Punyo Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection Antimicrobial Agents Chemother 49 2005 1337 1339
9. L. Poirel, T. Naas, D. Nicolas, and et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France Antimicrobial Agents Chemother 44 2000 891 897
10. J. Meletiadis, R. Al-Saigh, A. Velegraki, T.J. Walsh, E. Roilides, and L. Zerva Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model Antimicrobial Agents Chemother 56 2012 403 410
11. M. Tsala, S. Vourli, S. Kotsakis, and et al. Pharmacokinetic-pharmacodynamic modeling of meropenem against VIM producing Klebsiella pneumoniae isolates: clinical implications J Med Microbiol. 65 3 2016 211 218
12. J.L. Crandon, R.E. Ariano, S.A. Zelenitsky, A.M. Nicasio, J.L. Kuti, and D.P. Nicolau Optimization of meropenem dosage in the critically ill population based on renal function Intensive Care Med 37 2011 632 638
13. R. Kitzes-Cohen, D. Farin, G. Piva, and S.A. De Myttenaere-Bursztein Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients Int J Antimicrob Agents 19 2002 105 110
14. D.H. Pitkin, and E. Marin-Mazuelos Bioassay methods for antimicrobial and antifungal agents R. Schwalbe, L. Steele-Moore, A.C. Goodwin, Antimicrobial Susceptibility Testing Protocols 10th ed 2007 CRC Press Boca Raton, FL 313
15. M. Souli, F.V. Kontopidou, E. Papadomichelakis, I. Galani, A. Armaganidis, and H. Giamarellou Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital Clin Infect Dis 46 2008 847 854
16. A.S. Michalopoulos, I.G. Livaditis, and V. Gougoutas The revival of fosfomycin Int J Infect Dis 15 2011 e732 e739
17. S. Wadia, and B. Tran Colistin-mediated neurotoxicity BMJ Case Rep 2014 2014
18. B. Kitchel, J.K. Rasheed, A. Endimiani, and et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae Antimicrobial Agents Chemother 54 2010 4201 4207
19. W.A. Craig The pharmacology of meropenem, a new carbapenem antibiotic Clin Infect Dis 24 suppl 2 1997 S266 S275
20. L. Binder, H. Schworer, S. Hoppe, and et al. Pharmacokinetics of meropenem in critically ill patients with severe infections Ther Drug Monit 35 2013 63 70
21. C.C. Bulik, H. Christensen, P. Li, C.A. Sutherland, D.P. Nicolau, and J.L. Kuti Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model Antimicrobial Agents Chemother 54 2010 804 810
22. A. Markogiannakis, L.S. Tzouvelekis, M. Psichogiou, E. Petinaki, and G.L. Daikos Confronting carbapenemase-producing Klebsiella pneumoniae Future Microbiol 8 2013 1147 1161
23. F. Thalhammer, F. Traunmuller, I. El Menyawi, and et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients J Antimicrob Chemother 43 1999 523 527
24. I. Chytra, M. Stepan, J. Benes, and et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial Crit Care 16 2012 R113